The Claim
Liraglutide 3.0 mg, when added to insulin therapy in overweight or obese adults with type 2 diabetes, does not increase the risk of hypoglycemia and is associated with fewer hypoglycemic events compared to placebo, likely due to lower insulin requirements.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Liraglutide 3.0 mg combined with insulin in overweight or obese adults with type 2 diabetes does not raise the risk of low blood sugar. It actually leads to fewer episodes of low blood sugar than placebo because patients need less insulin.
See the scientific wording
Liraglutide 3.0 mg does not increase the risk of hypoglycemia when added to insulin therapy in overweight or obese adults with type 2 diabetes; instead, it is associated with fewer hypoglycemic events compared to placebo (336.1 vs. 441.7 documented symptomatic events per 100 patient-years), likely due to lower insulin requirements.
Liraglutide is a medicine that mimics a natural hormone (GLP-1) in the body. It works by helping the body release insulin only when blood sugar is high, and it also reduces appetite and slows digestion, leading to weight loss. Because blood sugar control improves, people need less injected insulin. Since less insulin is used, the risk of blood sugar dropping too low (hypoglycemia) decreases.
What the research says
1 studyThe study found that people with type 2 diabetes who took liraglutide along with insulin had fewer low blood sugar episodes than those who took placebo with insulin, because the liraglutide group needed less insulin, which lowers the risk of hypoglycemia.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.